Teva Pharmaceutical Industries ADR (TEVA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 09-2019 | 06-2019 | 03-2019 | 12-2018 | 09-2018 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -1,076,000 | -768,000 | -97,000 | -2,472,000 | 771,000 |
| Depreciation Amortization | 1,306,000 | 893,000 | 443,000 | 1,842,000 | 1,460,000 |
| Income taxes - deferred | -652,000 | -362,000 | N/A | -837,000 | -650,000 |
| Accounts receivable | N/A | N/A | N/A | 88,000 | N/A |
| Other Working Capital | -784,000 | -1,056,000 | -805,000 | -1,823,000 | -1,521,000 |
| Other Operating Activity | 1,416,000 | 1,178,000 | 571,000 | 5,648,000 | 2,019,000 |
| Operating Cash Flow | $210,000 | $-115,000 | $112,000 | $2,446,000 | $2,079,000 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -239,000 | -103,000 | -114,000 | 239,000 | -438,000 |
| Net Acquisitions | N/A | N/A | N/A | N/A | 880,000 |
| Purchase Of Investment | N/A | N/A | N/A | -119,000 | -56,000 |
| Other Investing Activity | 1,164,000 | 804,000 | 386,000 | 1,746,000 | 1,406,000 |
| Investing Cash Flow | $925,000 | $701,000 | $272,000 | $1,866,000 | $1,792,000 |
| Cash Flows From Financing Activities | |||||
| Change In Short Term Borrowing | 96,000 | N/A | N/A | -260,000 | -262,000 |
| Debt Issued | N/A | N/A | N/A | 4,434,000 | 4,434,000 |
| Debt Repayment | -1,715,000 | -157,000 | -126,000 | -7,446,000 | -6,989,000 |
| Dividend Paid | N/A | N/A | N/A | -22,000 | N/A |
| Other Financing Activity | -66,000 | -67,000 | -63,000 | -57,000 | -35,000 |
| Financing Cash Flow | $-1,685,000 | $-224,000 | $-189,000 | $-3,351,000 | $-2,852,000 |
| Exchange Rate Effect | 9,000 | 21,000 | -4,000 | -142,000 | -107,000 |
| Beginning Cash Position | 1,782,000 | 1,782,000 | 1,782,000 | 963,000 | 963,000 |
| End Cash Position | 1,241,000 | 2,165,000 | 1,973,000 | 1,782,000 | 1,875,000 |
| Net Cash Flow | $-541,000 | $383,000 | $191,000 | $819,000 | $912,000 |
| Free Cash Flow | |||||
| Operating Cash Flow | 210,000 | -115,000 | 112,000 | 2,446,000 | 2,079,000 |
| Capital Expenditure | -406,000 | -237,000 | -125,000 | -651,000 | -438,000 |
| Free Cash Flow | -196,000 | -352,000 | -13,000 | 1,795,000 | 1,641,000 |